Sugi Predict

Sugi Predict / Compounds / SCHEMBL4304713

SCHEMBL4304713

SCHEMBL4304713

CC(C)(C)OC(=O)N1C[C@H]2[C@@H]([C@H]1C(N)=O)C2(C)C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.34
▸ CHRM2 P08172 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33
▸ CTSV O60911 1/20 0.33
▸ CTSL P07711 1/20 0.33
▸ CTSB P07858 1/20 0.33
▸ ELANE P08246 1/20 0.33
▸ CMA1 P23946 1/20 0.33
▸ CTSS P25774 1/20 0.33
▸ CTSK P43235 1/20 0.33
▸ CTSF Q9UBX1 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ TPSAB1 Q15661 1/20 0.32
▸ TPSD1 Q9BZJ3 1/20 0.32
▸ TPSG1 Q9NRR2 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4311042 1.00 NR1H2 (0.34) NR1H2CHRM2CHRM1CHRM3CTSV
SCHEMBL13689098 0.88 HSD17B10 (0.37) NR1H2CHRM2CHRM1CHRM3HSD17B10
SCHEMBL14451045 0.88 HSD17B10 (0.37) NR1H2CHRM2CHRM1CHRM3HSD17B10
SCHEMBL9005877 0.88 HSD17B10 (0.37) NR1H2CHRM2CHRM1CHRM3HSD17B10
SCHEMBL14401914 0.88 HSD17B10 (0.37) NR1H2CHRM2CHRM1CHRM3HSD17B10
SCHEMBL4308133 0.88 HSD17B10 (0.37) NR1H2CHRM2CHRM1CHRM3HSD17B10
SCHEMBL16349058 0.88 HSD17B10 (0.37) NR1H2CHRM2CHRM1CHRM3HSD17B10
SCHEMBL8353738 0.88 HSD17B10 (0.37) NR1H2CHRM2CHRM1CHRM3HSD17B10
SCHEMBL13305538 0.88 HSD17B10 (0.37) NR1H2CHRM2CHRM1CHRM3HSD17B10
SCHEMBL4305518 0.87 NR1H2 (0.35) NR1H2CHRM2CHRM1CHRM3HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281331-A1 METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-12 — — US claimed
EP-2014648-A1 PROCESS FOR PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDUCT SALT THEREOF Sumitomo Chemical Company, Limited (JP) 2009-01-14 — — EP claimed
US-11124497-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-09-21 — — US disclosed
US-20090281331-A1 METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-12 — — US disclosed
EP-2014648-A1 PROCESS FOR PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDUCT SALT THEREOF Sumitomo Chemical Company, Limited (JP) 2009-01-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281331-A1 METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF C9, NPPA, ADH1C NR1H2 4250/4885CHRM2 1427/4885CHRM1 1013/4885
US-11124497-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL NR1H2 4184/4885CHRM2 4847/4885CHRM1 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.